

## **QurAlis Invited to Present at 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference**

**CAMBRIDGE, Mass., January 7, 2025** – [QurAlis Corporation](#) (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases, today announced that it has been invited to present at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025, in San Francisco, CA.

Kasper Roet, Ph.D., QurAlis’ chief executive officer and co-founder, will present a corporate overview on Monday, January 13, 2025 at 5:30PM PT at the Westin St. Francis in the Golden Gate room. The QurAlis corporate presentation can be accessed by visiting the presentations section of the Company’s website at [www.quralis.com](http://www.quralis.com).

### **About QurAlis Corporation**

At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a robust precision medicine pipeline with therapeutic candidates aimed at modifying severe disease pathology in defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers. For more information, please visit [www.quralis.com](http://www.quralis.com) or follow us on X @QurAlisCo or [LinkedIn](#).

### **Contact:**

Kathy Vincent  
kathy.vincent@quralis.com  
310-403-8951

###